ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2012-2-128-132ssmu-463Research ArticleОТ НАУКИ К ПРАКТИКЕFROM SCIENCE TO PRACTICEМаркеры прогноза лимфогенного метастазирования рака мочевого пузыряPrognostic markers of urinary bladder cancer lymphatic spreadПавловВ. Н.PavlovV. N.Izmailov75@mail.ruИзмайловА. А.IzmailovA. A.Izmailov75@mail.ruИзмайловаС. М.IzmailovaS. M.Izmailov75@mail.ruВиктороваТ. В.ViktorovaT. V.Izmailov75@mail.ruУрманцевМ. Ф.UrmantsevM. F.Izmailov75@mail.ru201228042012112128132Copyright © Павлов В.Н., Измайлов А.А., Измайлова С.М., Викторова Т.В., Урманцев М.Ф., 20122012Павлов В.Н., Измайлов А.А., Измайлова С.М., Викторова Т.В., Урманцев М.Ф.Pavlov V.N., Izmailov A.A., Izmailova S.M., Viktorova T.V., Urmantsev M.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/463

Проанализированы результаты лечения 104 пациентов с инвазивным раком мочевого пузыря за период с 2005 по 2009 г. Проведен молекулярно-генетический анализ полиморфных локусов генов цитохромов P450: CYP1А1 (A2455G), СYP1A2 (T-2464delT), глутатион S-трансферазы: GSTM1 (del), GSTP1 (A313G); репарации ДНК: XRCC1 (G28152A) у пациентов с инвазивным раком мочевого пузыря с лимфогенными метастазами и без них. Выявлены генотипы, ассоциированные с риском лимфогенного метастазирования.

Treatment results (2005—2009) for patients with invasive (N=104) urinary bladder carcinoma were analyzed. Molecular genetic analysis of cytochrome gene P450 polymorphous locus carried out: CYP1А1 (A2455G), СYP1A2 (T-2464delT), Glutathione S-transferase: GSTM1 (del), GSTP1 (A313G); DNA reparation: XRCC1 (G28152A) for patients with invasive urine bladder carcinoma with and without lymphogenic metastases was carried out. Genotypes associated with lyphogenic metastasis risk were identified.

рак мочевого пузыряпрогнозгенетические маркерыUrine bladder cancerprognosisgenetic markersReferencesАль-Шукри С.А., Ткачук В.Н., Волков Н.М., Дубина М.В. Прогностические молекулярно-генетические маркеры рака мочевого пузыря (обзор литературы) // Онкология. 2009. № 2. С. 78—84.Аль-Шукри С.А., Ткачук В.Н., Волков Н.М., Дубина М.В. Прогностические молекулярно-генетические маркеры рака мочевого пузыря (обзор литературы) // Онкология. 2009. № 2. С. 78—84.Глыбочко П.В., Понукалин А.Н., Шахпазян Н.К., Захарова Н.Б. Значение маркеров опухолевого роста и ангиогенеза в диагностике рака мочевого пузыря // Онкология. 2009. № 2. С. 56—60.Глыбочко П.В., Понукалин А.Н., Шахпазян Н.К., Захарова Н.Б. Значение маркеров опухолевого роста и ангиогенеза в диагностике рака мочевого пузыря // Онкология. 2009. № 2. С. 56—60.Androutsopoulos V.P., Tsatsakis A.M., Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention // BMC Cancer. 2009. V. 9. P. 187—189.Androutsopoulos V.P., Tsatsakis A.M., Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention // BMC Cancer. 2009. V. 9. P. 187—189.Babjuk M., Oosterlinck W., Sylvester R. et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Asso-ciation of Urology (EAU) // Eur. Urol. 2008. Aug. V. 54 (2). P. 303—314.Babjuk M., Oosterlinck W., Sylvester R. et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Asso-ciation of Urology (EAU) // Eur. Urol. 2008. Aug. V. 54 (2). P. 303—314.Brauers A., Buettner R., Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? // J. Urology. 2001. Mar. V. 165 (3) P. 808—810.Brauers A., Buettner R., Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? // J. Urology. 2001. Mar. V. 165 (3) P. 808—810.Gao W., Romkes M., Zhong S. et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene muta-tions and bladder cancer risk // Oncol. Rep. 2010. Jul. V. 24 (1). P. 257—262.Gao W., Romkes M., Zhong S. et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene muta-tions and bladder cancer risk // Oncol. Rep. 2010. Jul. V. 24 (1). P. 257—262.Golka K., Hermes M., Selinski S. et al. Susceptibility to uri-nary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure // Pharmacogenet. Genomics. 2009. Nov. V. 19 (11). P. 903—906.Golka K., Hermes M., Selinski S. et al. Susceptibility to uri-nary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure // Pharmacogenet. Genomics. 2009. Nov. V. 19 (11). P. 903—906.Grando J.P., Kuasne H., Losi-Guembarovski R. et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer // Clin. Exp. Med. 2009. Mar. V. 9 (1). P. 21—28.Grando J.P., Kuasne H., Losi-Guembarovski R. et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer // Clin. Exp. Med. 2009. Mar. V. 9 (1). P. 21—28.Herr H., Lee C., Chang S., Lerner S. Bladder Cancer Col-laborative Group. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collabora-tive group report // J. Urology. 2004. V. 171. P. 1823—1828.Herr H., Lee C., Chang S., Lerner S. Bladder Cancer Col-laborative Group. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collabora-tive group report // J. Urology. 2004. V. 171. P. 1823—1828.Herr H.W., Faulkner J.R., Grossman H.B. et al. Surgical factors influence bladder cancer outcomes: a cooperative group report // J. Clin. Oncol. 2004. V. 22. P. 2781—2789.Herr H.W., Faulkner J.R., Grossman H.B. et al. Surgical factors influence bladder cancer outcomes: a cooperative group report // J. Clin. Oncol. 2004. V. 22. P. 2781—2789.Kim Y.K., Kim W.J. Epigenetic markers as promising prog-nosticators for bladder cancer // J. Int. Urology. 2009. Jan. V. 16 (1). P. 17—22.Kim Y.K., Kim W.J. Epigenetic markers as promising prog-nosticators for bladder cancer // J. Int. Urology. 2009. Jan. V. 16 (1). P. 17—22.Grando J.P., Kuasne H., Losi-Guembarovski R. et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer // Clin. Exp. Med. 2009. Mar. V. 9 (1). P. 21—28.Grando J.P., Kuasne H., Losi-Guembarovski R. et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer // Clin. Exp. Med. 2009. Mar. V. 9 (1). P. 21—28.Leissner J., Allhoff E.P., Hohenfellner R., Wolf H.K. Rank-ing of pelvic lymphadenectomy in therapy and prognosis of carcinoma of the bladder // Akt. Urol. 2003. V. 34. P. 392—397.Leissner J., Allhoff E.P., Hohenfellner R., Wolf H.K. Rank-ing of pelvic lymphadenectomy in therapy and prognosis of carcinoma of the bladder // Akt. Urol. 2003. V. 34. P. 392—397.Leissner J., Ghoneim M.A., Abol-Eneim H. et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study // J. Urology. 2004. V. 171. P. 139—144.Leissner J., Ghoneim M.A., Abol-Eneim H. et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study // J. Urology. 2004. V. 171. P. 139—144.Leissner J., Hohenfellner R., Thüroff J.W., Wolf H.K. Lym-phadenectomy in patients with transitional cell carcinoma of the urinary bladder: significance for staging and prognosis // BJU Int. 2000. V. 85. P. 817—821.Leissner J., Hohenfellner R., Thüroff J.W., Wolf H.K. Lym-phadenectomy in patients with transitional cell carcinoma of the urinary bladder: significance for staging and prognosis // BJU Int. 2000. V. 85. P. 817—821.Mittal R.D., Singh R., Manchanda P.K. et al. XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy // Cancer Biol. Ther. 2008. May. V. 7 (5). P. 645—650.Mittal R.D., Singh R., Manchanda P.K. et al. XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy // Cancer Biol. Ther. 2008. May. V. 7 (5). P. 645—650.Somali Sanyal, Petra J. de Verdier, Gunnar Steineck et al. Polimorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms // Acta Oncologica. 2007. V. 46. P. 31—41.Somali Sanyal, Petra J. de Verdier, Gunnar Steineck et al. Polimorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms // Acta Oncologica. 2007. V. 46. P. 31—41.Stenzl A., Cowan N.C., De Santis M. et al. Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma // Actas Urol. Esp. 2010. Jan. V. 34 (1). P. 51—62.Stenzl A., Cowan N.C., De Santis M. et al. Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma // Actas Urol. Esp. 2010. Jan. V. 34 (1). P. 51—62.Steven K., Poulsen A.L. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only // J. Urology. 2007. V. 178. P. 1218—1223.Steven K., Poulsen A.L. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only // J. Urology. 2007. V. 178. P. 1218—1223.Wang C., Sun Y., Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis // J. Urology. 2008. Oct. V. 72. P. 869—872.Wang C., Sun Y., Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis // J. Urology. 2008. Oct. V. 72. P. 869—872.

The authors declare that there are no conflicts of interest present.